Table 1 MPN Patients’ Demographics by Smoking Status
From: Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care
Demographics | Current/Former (N = 181) | Never (N = 254) | Total (N = 435) | p-value |
|---|---|---|---|---|
Age (Mean, Range) | 61.5 (38.0–86.0) | 60.1 (26.0–84.0) | 60.7 (26.0–86.0) | 0.1879 |
Gender (n, %) | Â | Â | Â | 0.0578 |
 Male | 55 (30.4%) | 56 (22.0%) | 111 (25.5%) |  |
 Female | 126 (69.6%) | 198 (78.0%) | 324 (74.5%) |  |
Country of Residence (n, %) | Â | Â | Â | 0.1333 |
 US | 115 (63.5%) | 175 (68.9%) | 290 (66.7%) |  |
 Canada | 10 (5.5%) | 17 (6.7%) | 27 (6.2%) |  |
 Australia | 30 (16.6%) | 21 (8.3%) | 51 (11.7%) |  |
 United Kingdom | 10 (5.5%) | 17 (6.7%) | 27 (6.2%) |  |
 Other | 16 (8.8%) | 24 (9.4%) | 40 (9.2%) |  |
Language (n, %) | Â | Â | Â | 0.3864 |
 English | 166 (91.7%) | 239 (94.1%) | 405 (93.1%) |  |
 Spanish | 3 (1.7%) | 1 (0.4%) | 4 (0.9%) |  |
 Other | 12 (6.6%) | 14 (5.5%) | 26 (6.0%) |  |
MPN subtype (n, %) | Â | Â | Â | 0.0623 |
 ET | 44 (24.3%) | 75 (29.5%) | 119 (27.4%) |  |
 PV | 75 (41.4%) | 118 (46.5%) | 193 (44.4%) |  |
 MF | 62 (34.3%) | 61 (24.0%) | 123 (28.3%) |  |
MF type (n, %)a | Â | Â | Â | 0.2383 |
 Primary myelofibrosis | 34 (54.8%) | 24 (39.3%) | 58 (47.2%) |  |
 Post-ET myelofibrosis | 18 (29.0%) | 23 (37.7%) | 41 (33.3%) |  |
 Post-PV myelofibrosis | 10 (16.1%) | 14 (23.0%) | 24 (19.5%) |  |
MPN duration (n, %) | Â | Â | Â | 0.8305 |
  < ½ Year | 6 (3.3%) | 13 (5.2%) | 19 (4.4%) |  |
 ½ - 3 Years | 55 (30.4%) | 72 (28.6%) | 127 (29.3%) |  |
 3–10 Years | 65 (35.9%) | 92 (36.5%) | 157 (36.3%) |  |
  > 10 Years | 55 (30.4%) | 75 (29.8%) | 130 (30.0%) |  |
Prior bone marrow transplantation (n, %) | 6 (3.3%) | 0 (0.0%) | 6 (1.4%) | 0.0049 |
Splenomegaly (n, %) | 56 (40.3%) | 71 (34.3%) | 127 (36.7%) | 0.4798 |
Prior splenectomy | 6 (3.3%) | 2 (0.8%) | 8 (1.9%) | 0.0725 |
Prior thrombosis (n, %) | Â | Â | Â | 0.5062 |
 Blood Clot in Deep Veins of the Leg or Arm | 13 (7.3%) | 24 (9.6%) | 37 (8.7%) |  |
 Blood Clot in Veins of the Head | 1 (0.6%) | 7 (2.8%) | 8 (1.9%) |  |
 Blood Clot in Veins of the Abdomen | 7 (3.9%) | 13 (5.2%) | 20 (4.7%) |  |
 Stroke or Transient Ischemic Attack | 15 (8.4%) | 21 (8.4%) | 36 (8.4%) |  |
 Heart Attack | 5 (2.8%) | 5 (2.0%) | 10 (2.3%) |  |
Prior hemorrhage (n, %) | 25 (13.8%) | 31 (12.3%) | 56 (12.9%) | 0.3913 |
Current treatment of MPN (n, %) | ||||
 Aspirin | 118 (65.2%) | 200 (78.7%) | 318 (73.1%) | 0.0021 |
 Hydroxyurea | 56 (30.9%) | 88 (34.6%) | 144 (33.1%) | 0.4696 |
 Interferon | 8 (4.4%) | 11 (4.3%) | 19 (4.4%) | 1.0000 |
 Ruxolitinib | 41 (22.7%) | 54 (21.3%) | 95 (21.8%) | 0.7258 |
 Anagrelide | 9 (5.0%) | 6 (2.4%) | 15 (3.4%) | 0.1833 |
 Phlebotomy requirement | 34 (18.8%) | 64 (25.2%) | 98 (22.5%) | 0.1305 |
 RBC transfusion requirement | 15 (8.3%) | 6 (2.4%) | 21 (4.8%) | 0.0058 |
Comorbidity (n, %) | ||||
 Anemia | 101 (56.1%) | 101 (40.1%) | 202 (46.8%) | 0.0004 |
 Heart disease | 23 (12.7%) | 25 (9.8%) | 48 (11.0%) | 0.5488 |
 Chronic obstructive pulmonary disorder | 11 (6.1%) | (1 (0.4%) | 12 (2.8%) | 0.0004 |
 Current opioid use for pain management | 41 (23.6%) | 27 (11.2%) | 68 (16.4%) | 0.0011 |